Arca
Skip to content
Tools
Tools

Type 1 diabetes

Drug research and approvals for type 1 diabetes: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 430 studies of type 1 diabetes are recruiting on ClinicalTrials.gov, Health Canada has authorized 84 drug trials for it since 2013, FDA has 4 approved and 11 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 430
  • Trials authorized in Canada: 84
  • FDA orphan approvals: 4
  • EU medicines: 1

Recruiting now

Newest posted first, of 430 recruiting on ClinicalTrials.gov ↗

How its trials ended

3,244 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 739 whose ending is known, 56% met their primary endpoint, 7% missed it and 37% stopped early.

  • Completed, result not reported1,67252%
  • Ongoing54617%
  • Met its primary endpoint41313%
  • Status unknown2879%
  • Stopped: other or unclear1715%
  • Missed its primary endpoint502%
  • Stopped: enrollment or feasibility481%
  • Stopped: sponsor or business decision221%
  • Stopped: lack of efficacy211%
  • Stopped: funding12<1%
  • Stopped: safety2<1%

Trials authorized in Canada

The 10 newest of 84; search them all in Canada trials
Jul 15, 2026A phase 1/2, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, and efficacy of VV-14300 (adeno-associated virus…VV-14300 / Actemra / Avtozma / TyenneKriya TherapeuticsOngoing
May 20, 2026Changes to body composition with semaglutide vs. placebo in adults with type 1 diabetes and overweight/obesity: a double-blinded, randomized, parallel…WegovyResearch Institute of The McGill University Health CentrePending
Dec 19, 2025Fully closed loop glucose control in adults with type 1 diabetes using tirzepatide: a randomized, multi-center, open-label, non-inferiority, parallel trial.TirzepatideResearch Institute of The McGill University Health CentrePending
Nov 26, 2025A phase 3, double-blind, randomized, placebo-controlled study of baricitinib to preserve beta cell function in participants newly diagnosed with type 1…Baricitinib (LY3009104)Eli LillyOngoing
Oct 23, 2025A phase 3, double-blind, randomized, placebo-controlled study of baricitinib to delay stage 3 type 1 diabetes in at-risk participants aged =1 to <36 years…Baricitinib (LY3009104)Eli LillyOngoing
Aug 15, 2025A randomized, double-blind, phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with…Tzield (teplizumab (SAR446681))Sanofi-Aventis Canada IncOngoing
May 29, 2025A 26-week study comparing the efficacy and safety of once-weekly insulin icodec and once-daily insulin glargine U100, both in combination with insulin aspart,…Insulin icodecNovo NordiskOngoing
Mar 20, 2025A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and long-term safety of tirzepatide once…Tirzepatide (LY3298176)Eli LillyOngoing
Feb 11, 2025A study to assess the pharmacodynamics, pharmacokinetics, and tolerability of XRS-0104 (glucagon) injectionGlucagon (XRS-0104)Beta BionicsClosed
Jan 8, 2025Jak inhibitors to preserve c-peptide production in new onset T1D: a phase 2 multi-center, randomized, double-blind, placebo-controlled study to evaluate the…Abrocitinib (PF-04965842) / Ritlecitinib (PF-06651600)The Hospital for Sick ChildrenOngoing

FDA orphan designations

Approved first, then open designations, newest first
Jun 12, 2026TzieldTo delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 type 1…Provention Bio, Inc.Approved
Apr 20, 2026TzieldTo delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 type 1 diabetesProvention Bio, Inc.Approved
Jun 28, 2023LantidraTreatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe…CellTrans Inc.Approved
Nov 17, 2022TzieldTo delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetesProvention Bio, Inc.Approved
Mar 9, 2020Purified Human Allogeneic Pancreatic Islets of LangerhansTreatment of Brittle Type 1 DiabetesUniversity of MinnesotaDesignated
Jul 22, 2019Allogeneic Human Pancreatic Islets of LangerhansTreatment of Brittle Type 1 DiabetesHospital of the University of Pennsylvania (Penn Medicine)Designated
Jun 4, 2019Allogeneic Human Pancreatic Islets of LangerhansTreatment of Brittle Type 1 DiabetesUniversity of California, San FrancicoDesignated
May 1, 2019Allogeniec Human Pancreatic Islets of LangerhansTreatment of brittle type 1 diabetesDiabetes Research Institute & Cell Transplant Center, Univ of MiamiDesignated
May 1, 2019Purified Allogeneic Human Pancreatic Islets of LangerhansTreatment of Brittle Type 1 DiabetesUniversity of ChicagoDesignated
Jan 12, 2017MethyldopaTreatment of type 1 diabetes in DQ8 positive patients with residual beta cell functionIM Therapeutics LLCDesignated
Mar 3, 2015alpha1-proteinase inhibitor (human)Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.Grifols Therapeutics, Inc.Designated
Dec 20, 2013CD40/CD80/CD86 modified autologous dendritic cell therapyTreatment Type 1 diabetes mellitus patients with residual beta cell functionDiaVacs, Inc.Designated
May 30, 2013AbataceptTreatment of type 1 diabetes mellitus patients with residual beta cell functionOrban Biotech LLCDesignated
Feb 11, 2013Human insulin beta chain peptide with incomplete Freund's…Treatment of Type 1 diabetes patients with residual beta cell functionOrban Biotech, LLCDesignated
Apr 30, 2010Ex-vivo cultered adult human mesenchymal stem cellsTreatment of Type 1 diabetes patients with residual beta cell functionMesoblast, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Jan 8, 2026TeizeildTeplizumabSanofi Winthrop IndustrieEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.